Literature DB >> 15191417

Differential neural control of glomerular ultrafiltration.

Kate M Denton1, Susan E Luff, Amany Shweta, Warwick P Anderson.   

Abstract

The renal nerves constrict the renal vasculature, causing decreases in renal blood flow (RBF) and glomerular filtration rate (GFR). Whether renal haemodynamics are influenced by changes in renal nerve activity within the physiological range is a matter of debate. We have identified two morphologically distinct populations of nerves within the kidney, which are differentially distributed to the renal afferent and efferent arterioles. Type I nerves almost exclusively innervate the afferent arteriole whereas type II nerves are distributed equally on the afferent and efferent arterioles. We have also demonstrated that type II nerves are immunoreactive for neuropeptide Y, whereas type I nerves are not. This led us to hypothesize that, in the kidney, distinct populations of nerves innervate specific effector tissues and that these nerves may be selectively activated, setting the basis for the differential neural control of GFR. In physiological studies, we demonstrated that differential changes in glomerular capillary pressure occurred in response to graded reflex activation of the renal nerves, compatible with our hypothesis. Thus, sympathetic outflow may be capable of selectively increasing or decreasing glomerular capillary pressure and, hence, GFR by differentially activating separate populations of renal nerves. This has important implications for our understanding of the neural control of body fluid balance in health and disease.

Entities:  

Mesh:

Year:  2004        PMID: 15191417     DOI: 10.1111/j.1440-1681.2004.04002.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Residual renal function after partial or radical nephrectomy for renal cell carcinoma.

Authors:  David Chapman; Ron Moore; Scott Klarenbach; Branko Braam
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

2.  Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study.

Authors:  Maria Baltazi; Niki Katsiki; Christos Savopoulos; Fotios Iliadis; George Koliakos; Apostolos I Hatzitolios
Journal:  Am J Cardiovasc Dis       Date:  2011-05-20

Review 3.  Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.

Authors:  Natalia Madetko; Weronika Marzec; Agata Kowalska; Dominika Przewodowska; Piotr Alster; Dariusz Koziorowski
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

Review 4.  Edema formation in congestive heart failure and the underlying mechanisms.

Authors:  Zaid Abassi; Emad E Khoury; Tony Karram; Doron Aronson
Journal:  Front Cardiovasc Med       Date:  2022-09-27

5.  IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Authors:  Josephe A Honorat; Lars Komorowski; Keith A Josephs; Kai Fechner; Erik K St Louis; Shannon R Hinson; Sabine Lederer; Neeraj Kumar; Avi Gadoth; Vanda A Lennon; Sean J Pittock; Andrew McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.